Medtronic touts CRT data

Meta-analyses of Medtronic-sponsored studies show the clinical and economic benefits of its cardiac resynchronization therapy devices. Medtronic (NYSE:MDT) yesterday touted the results of meta-analyses of a group of company-sponsored studies of its cardiac resynchronization therapy devices, saying the data show the clinical and economic value its CRT portfolio. MedtronicNews Well, Cardiac Rhythm Managementread more
Source: Mass Device - Category: Medical Equipment Authors: Source Type: news